PACS Group Inc is a post-acute healthcare company primarily focused on delivering high-quality skilled nursing care through a portfolio of independently operated facilities Its is a nursing providers in the United States based on number of facilities, with over 200 post-acute care facilities across nine states serving over 20,000 patients daily. It also provide senior care, assisted living, and independent living options in some of communities.
2023
32.4K+
LTM Revenue $4.1B
LTM EBITDA $403M
$4.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
PACS Group has a last 12-month revenue of $4.1B and a last 12-month EBITDA of $403M.
In the most recent fiscal year, PACS Group achieved revenue of $3.1B and an EBITDA of $233M.
PACS Group expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See PACS Group valuation multiples based on analyst estimatesFY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $2.4B | $3.1B | XXX | XXX | XXX |
Gross Profit | $187M | $401M | XXX | XXX | XXX |
Gross Margin | 8% | 13% | XXX | XXX | XXX |
EBITDA | $255M | $233M | XXX | XXX | XXX |
EBITDA Margin | 11% | 7% | XXX | XXX | XXX |
Net Profit | $47.9M | $150M | XXX | XXX | XXX |
Net Margin | 2% | 5% | XXX | XXX | XXX |
Net Debt | n/a | $441M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, PACS Group's stock price is $9.
PACS Group has current market cap of $1.5B, and EV of $4.1B.
See PACS Group trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$4.1B | $1.5B | XXX | XXX | XXX | XXX | $1.70 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, PACS Group has market cap of $1.5B and EV of $4.1B.
PACS Group's trades at 1.0x LTM EV/Revenue multiple, and 10.0x LTM EBITDA.
Analysts estimate PACS Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for PACS Group and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $4.1B | XXX | XXX | XXX |
EV/Revenue | 1.3x | XXX | XXX | XXX |
EV/EBITDA | 17.4x | XXX | XXX | XXX |
P/E | 12.9x | XXX | XXX | XXX |
P/E/Growth | 0.2x | XXX | XXX | XXX |
EV/FCF | -37.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpPACS Group's NTM/LTM revenue growth is 14%
PACS Group's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $7K for the same period.
Over next 12 months, PACS Group's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate PACS Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for PACS Group and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | 28% | XXX | XXX | XXX | XXX |
EBITDA Margin | 7% | XXX | XXX | XXX | XXX |
EBITDA Growth | -9% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | 21% | XXX | XXX | XXX | XXX |
Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
Opex per Employee | $7K | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | 7% | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
Opex to Revenue | 8% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Burjeel Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
PureHealth | XXX | XXX | XXX | XXX | XXX | XXX |
Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
Ramsay Health | XXX | XXX | XXX | XXX | XXX | XXX |
Compass Pathways | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PACS Group acquired XXX companies to date.
Last acquisition by PACS Group was XXXXXXXX, XXXXX XXXXX XXXXXX . PACS Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was PACS Group founded? | PACS Group was founded in 2023. |
Where is PACS Group headquartered? | PACS Group is headquartered in United States of America. |
How many employees does PACS Group have? | As of today, PACS Group has 32.4K+ employees. |
Who is the CEO of PACS Group? | PACS Group's CEO is Mr. Jason Murray. |
Is PACS Group publicy listed? | Yes, PACS Group is a public company listed on NYS. |
What is the stock symbol of PACS Group? | PACS Group trades under PACS ticker. |
When did PACS Group go public? | PACS Group went public in 2024. |
Who are competitors of PACS Group? | Similar companies to PACS Group include e.g. Burjeel Holdings, PureHealth, Integral Diagnostics, Ramsay Health. |
What is the current market cap of PACS Group? | PACS Group's current market cap is $1.5B |
What is the current revenue of PACS Group? | PACS Group's last 12-month revenue is $4.1B. |
What is the current EBITDA of PACS Group? | PACS Group's last 12-month EBITDA is $403M. |
What is the current EV/Revenue multiple of PACS Group? | Current revenue multiple of PACS Group is 1.0x. |
What is the current EV/EBITDA multiple of PACS Group? | Current EBITDA multiple of PACS Group is 10.0x. |
What is the current revenue growth of PACS Group? | PACS Group revenue growth between 2023 and 2024 was 28%. |
Is PACS Group profitable? | Yes, PACS Group is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.